Newsletter · · Ashutosh Agarwal

AstraZeneca Buys a 2 Billion Dollar Summit Stake Instead of a Takeover - The Biotech Patent Cliff & M&A - Week of October 2, 2026

The Biotech Patent Cliff & M&A for the week of October 2, 2026. Podcast synthesis on AstraZeneca's $2B minority stake in Summit Therapeutics at a 19% premium, the shift toward China-sourced licensing and co-funded trials over outright takeovers, Merck's $400M pre-clinical KRAS bet, the Sanofi and Regeneron Dupixent extension, and MFN pricing pressure reaching the mid-caps.

The Biotech Patent Cliff & M&A

Week of October 2, 2026: AstraZeneca Buys a 2 Billion Dollar Summit Stake Instead of a Takeover

TL;DR

  • AstraZeneca put $2B into Summit Therapeutics at a 19% premium, but it is a minority stake, not a takeover. Four days later it pulled Daiichi Sankyo into a new Phase 3 deal with Summit. Big pharma is paying to get close to the PD-1/VEGF drug class without buying anyone outright. The HARMONi-3 readout is now the biggest single event in SMID biotech.
  • China-sourced licensing replaced M&A as the main way to buy pipeline this week. Novo paid $300M upfront for a pre-clinical oral obesity pill from Hengrui. Merck paid $400M upfront for a pre-clinical oral KRAS drug from SciBrunch. Novartis paid $575M upfront for an mRNA immune-cell drug from Abogen. Podcasts put China at roughly half of all global drug-licensing value.
  • The patent-cliff buyers stayed quiet on podcasts again. Pfizer, AbbVie, J&J, Gilead and Bristol-Myers had no strategic airtime. The 100% pharma tariff that went live Tuesday got zero podcast discussion. Vertex has still not publicly confirmed closing its Crinetics deal. XBI, the main biotech ETF, finished the week down 0.36%.

The hook

For two years the patent-cliff trade has had one assumption baked in: big pharma will run out of time and buy its way out with large takeovers. This week the biggest cheque in biotech went in as a minority stake rather than a takeover.

AstraZeneca wrote Summit Therapeutics a $2 billion cheque and did not buy the company. Novo Nordisk said last week it was "quite interested" in M&A. This week it signed another license, not an acquisition. Merck, the company with the largest single cliff (Keytruda), spent $400M upfront on a molecule that has never been in a human. None of that is a white flag. It is pharma deciding that the cheapest way to fill a revenue gap is to buy options rather than whole companies.

That changes who wins. Let's get into it.

What's new

1. AstraZeneca's $2B Summit stake: a premium price without a takeover

The deal. AstraZeneca is buying about $2B of Summit convertible preferred stock. It converts at $18.36 per common share, which is the five-day average price plus 10%. Citi calls it a 19% premium to the last close. The stake comes with:

  • a clinical collaboration pairing Summit's ivonescimab with AZ's Claudin 18.2 antibody-drug conjugate (ADC), sonesitatug vedotin, in GI cancers;
  • a non-binding "memorandum of understanding" (MOU) for more AZ combinations;
  • no milestones and no royalties.

Summit jumped 15% after hours to $17.85. (The Fly, Sept 28) On Friday a second leg landed: Summit, AZ and Daiichi Sankyo will test ivonescimab with Datroway (a TROP2 ADC), starting with a Phase 3 in first-line triple-negative breast cancer (wire report, The Fly, Oct 2).

Quick definitions. A PD-1/VEGF bispecific is one antibody that does two jobs. It takes the brakes off the immune system, which is what Keytruda does, and it starves tumours of blood vessels. Ivonescimab, licensed from China's Akeso, is the furthest along. In 2024 it beat Keytruda head-to-head in a Chinese lung-cancer trial. HARMONi-3 is Summit's global lung-cancer Phase 3, and its results decide whether this drug class becomes the next backbone of cancer treatment.

The best discussion of the week came from Biotech Hangout, "Episode 198 - October 2, 2026". Two of the show's analyst hosts took opposite sides (pundit/analyst commentary, not company insiders).

The bull, Eric, compared the deal to the Regeneron–Sanofi extension announced the same week (more below): "if Regeneron and Sanofi is sort of like an old couple cruising to a slow stop, maybe I'm hopeful that Summit and AstraZeneca is a young couple on a raging honeymoon." His sharpest point was about valuation:

"Just a few months ago, this company tried to raise about $500 million in the public markets... they kind of came up short. So, here's AZ giving them $2 billion at a premium and all this access to combination drugs and clinical expertise."

He put the obvious question to Summit: has AZ seen any unpublished HARMONi-3 data? Summit's answer was "no, definitively not." So there is a gap between what a strategic buyer will pay and what public investors will pay. His conclusion: "potentially the biggest binary event I've ever seen in the history of biotechnology."

The skeptic, Sam, took the other side.

  • He recalled a rumoured $15 billion AZ–Summit deal "about a year or so ago" that never happened.
  • He argued AZ "wanted to have some skin in the PD-1 VEGF game," while Summit "was running out of cash."
  • He put AZ's stake at about 10% ownership.
  • The new element, he said, is that AZ is co-funding the trials. He checked his firm's deals database for supply-and-collaboration deals and "couldn't find one where the provider of the drug, say if it's a Merck with their Keytruda... is actually paying anything for the conduct of the R&D or the trials."
  • He reported mixed signals on timing: some investors think HARMONi-3 slips to next year, others say "any day now." Eric's view was that a readout next week "would be very, very awkward" for both companies, so late this quarter or early next year looks more likely.

Why it matters for the book.

  • For the takeout thesis, this is a mild negative dressed up as a positive. It is the clearest sign yet that big pharma would rather pay a premium for a minority stake plus trial access than pay a 50–100% control premium before Phase 3 data.
  • Expect this structure to spread: equity stake, co-funded trials, an MOU for more. It is cheaper than M&A, it does not require antitrust review, and it keeps the buyer's options open.
  • For SMMT holders, the funding risk is gone and the stock is now a pure bet on the data. The sell side is split. Citi raised its target to $43 (Buy). Barclays raised to only $20 (Equal Weight).

2. China is now where pharma shops for early-stage drugs, and podcasts put numbers on it

Three licensing deals this week paid large sums upfront for molecules that are pre-clinical or have no human efficacy data yet (all from wire reports):

Buyer Seller Asset Upfront Total deal value
Novo Nordisk Jiangsu Hengrui HRS-1596, once-weekly oral GLP-1/GIP pill, ready for Phase 1 $300M up to $2.6B + royalties
Merck SciBrunch SPR2015, pre-clinical oral KRAS G12D inhibitor $400M up to $2.13B
Novartis Abogen ABO2203, in-body mRNA B-cell engager for autoimmune disease $575M up to $7.2B in milestones

Merck will book the $400M as a Q3 pre-tax charge of about $0.13 per share, on both GAAP and non-GAAP figures.

The structural picture came from two very different shows.

On the Sinica Podcast, "From Barefoot Doctors to Biologics: Dr. Ruby Wang on China's Healthcare Revolution" (Sept 29), host Kaiser Kuo set out the scale (journalist/host): last year "Chinese companies signed something like 186 out-licensing deals with a disclosed value of around $137 billion. That is roughly half of all out-licensing value globally and close to 10 times what it was in 2021." He named Pfizer, Bristol-Myers, AstraZeneca, GSK and Lilly as buyers.

His guest Dr. Ruby Wang is an NHS physician, former UK health lead in Beijing and a China healthcare consultant (industry expert). She said China's share of out-licensing deals worth more than $50M went from 5% to 50% in the first half of 2026. She ranked China strongest in oncology (ADCs, cell therapies), then metabolic drugs ("China's producing very cheap GLP-1s... dual action, triple action"), with immunology still lagging.

On the Grow Everything Biotech Podcast, "200. That's One Cell of a Machine: Jason Kelly of Ginkgo Automates Labs to Accelerate Discovery" (Sept 25), Ginkgo CEO Jason Kelly was more alarmed (operator; also former chair of the US National Security Commission on Emerging Biotechnology):

"We've gone from effectively 0% of acquired new drug assets and less than $2 billion worth back in five years ago, coming from China to last year, or 130 billion and 48%. Like crazy shift to moving the startup ecosystem to China."

He backs the proposed BINSA bill, which would add biotech to the outbound-investment review regime (the COINS Act). He said it would not ban deals, but they "should be like checked before we just like ship all of our capital to China."

A real-world flashpoint. The Readout Loud, "415: Mistrust in science and a juicy gene-editing lawsuit" (Oct 1) covered Beam Therapeutics' lawsuit against Chinese biotech Yoltec. Beam alleges a former scientist accessed trade secrets "on weekends late at night" before co-founding Yoltec. Yoltec then licensed assets into a new US company backed by US venture investors that competes directly with Beam. STAT's Adam Feuerstein (journalist) called it his "favorite story of the week" because "it just strikes to the heart of... whether it's a fair level playing field."

On Novo's deal specifically, the host of On The Pen GLP-1 News, "They TRIPLED Wegovy Dose, Does it Beat Zepbound?" (Oct 1) made a good point (pundit). Paying $300M upfront for something that "hasn't even given us any kind of human efficacy data" suggests Novo may be "really buying access to something bigger." That would be Hengrui's know-how on making a peptide work as a once-weekly pill. The episode also explained why this matters to Novo: the Wegovy pill uses roughly 10x as much semaglutide per day as the weekly shot.

Why it matters for the book.

  • Every dollar spent on cheap early-stage Chinese assets is a dollar not spent on a US SMID-cap takeout at a 60–100% premium. That pressures exits for early- and mid-stage US biotechs in crowded classes (GLP-1s, KRAS, autoimmune).
  • The flip side is scarcity value. US companies with late-stage or approved assets in these same classes gain, because the Chinese supply is mostly early-stage.
  • Policy is the swing factor. Wire and web reports say the Treasury rule on China licensing is still in draft and is expected to keep most in-licensing allowed. That is good for buyers, and the BINSA push is the counterweight. We could not verify these policy reports with a citable source.

3. Merck's $400M bet on a pre-clinical KRAS pill is a read-through to Revolution Medicines

No podcast connected these two stories this week, so this is our analysis. Merck paid $400M upfront (wire report) for a KRAS G12D inhibitor that has not reached the clinic. KRAS G12D is the most common mutation in pancreatic cancer. Revolution Medicines (RVMD) already has an approved drug that targets RAS broadly: daraxonrasib, brand name Rasonque, approved Aug 26 for metastatic pancreatic cancer. It also has a G12D-specific drug in the clinic.

If a pre-clinical G12D pill is worth $400M upfront and up to $2.13B to the most cliff-exposed big pharma, the market's value for RVMD's late-stage, already-commercial RAS franchise looks well supported. The podcasts were thin here.

  • OncLive On Air ran an "FDA Approval Insights" episode on daraxonrasib (OncLive On Air, Sept 30), aimed at doctors rather than investors.
  • Crain's Daily Gist (Crain's Daily Gist, Sept 25) covered why RVMD left Illinois for California.
  • UBS started RVMD at Buy with a $265 target, citing a strong launch (wire report).
  • Still no bid rumour.

Merck news on the clinical side was mixed.

  • Positive: on OncoPharm, "Lirafugratinib + LITESPARK011" (Oct 1), an oncologist host went through the newly approved Welireg plus lenvatinib combination in second-line kidney cancer (clinician commentary):
    • progression-free survival hazard ratio 0.70 (95% CI 0.59–0.84), meaning a 30% lower risk of the disease progressing;
    • response rate 53% vs 40%;
    • 21% vs 11% of patients stopping treatment because of side effects;
    • heart failure 4% vs under 1%;
    • no clear survival benefit yet (OS HR 0.85, CI 0.68–1.05).
  • The upshot: Welireg is useful for extending Merck's oncology franchise, but it does not replace Keytruda's revenue.
  • Negative: Merck and Daiichi withdrew their I-DXd application in small-cell lung cancer after FDA said the IDeate-Lung01 data were not enough for accelerated approval (wire report).
  • The street keeps raising targets anyway: Scotiabank to $180 from $155, Jefferies to $177, UBS $175 (wire reports).

For the seventh straight week, we found no US conversion numbers for Keytruda Qlex (the under-the-skin version), on podcasts or in news. This is still the biggest blind spot in the cliff debate.

4. Sanofi and Regeneron extend the Dupixent franchise instead of fighting over it

From the same Biotech Hangout, "Episode 198" (analyst hosts): Sanofi and Regeneron struck a deal covering four new antibodies in Dupixent's pathway, aimed at longer-acting successors to their blockbuster eczema and asthma drug.

  • $1 billion upfront to Regeneron and up to $7 billion in milestones, with a 50/50 global profit split.
  • The lead program targets IL-13 and is "planning on moving into pivotal studies." The others include an IL-13/IL-4 bispecific and a long-acting IL-4 receptor antibody "they call SuperDupy."

The patent-cliff detail is the useful part. Sam said Sanofi's CFO now believes they can push generic competition "a few years beyond the 2031 composition of matter date." His firm's patent group had already concluded in May that Dupixent protection "can be pushed to 2037, late 2037."

The buy side was unimpressed. Sanofi stock fell, and one buy-side friend described the deal as "an old married couple driving their car, taking the foot off the gas and coming to a stop in the middle of the road in silence."

Why it matters. Dupixent is one of the largest franchises facing loss of exclusivity (LOE) late this decade. If its protection really runs into 2037, Sanofi's cliff moves out six years. That would reduce Sanofi's need for big M&A, which is bad news for SMID immunology names hoping Sanofi will buy them.

5. Drug pricing: an operator view from inside the MFN talks

Insider commentary (operators):

  • On Citeline Podcasts, "Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era" (Sept 28), Boehringer Ingelheim's US Human Pharma president Brian Hilberdink said:
    • BI was one of the 17 companies approached for "most favored nation" (MFN) pricing deals, which tie US prices to lower prices abroad.
    • It had three products go through the Medicare negotiation process created by the Inflation Reduction Act (IRA).
    • Launch economics have flipped: new drugs used to get covered first and negotiated later; now they can be blocked until a price is agreed.
    • Boehringer lost exclusivity on Ofev in April and moved patients to its successor, Jascayd, ahead of it. He called that "just perfect lifecycle management." It is a textbook version of the cliff defence Merck is trying with Keytruda Qlex.
  • On Biotech Hangout, "Episode 197 - September 25, 2026" (published last Friday, after our last issue), Roivant CEO Matt Gline, a regular on the show, said the MFN wave is spreading down the market:

"I think we don't have an MFN agreement with the government today. I suspect given what we're seeing around us that like it's sort of coming for the mid-caps and it may be a conversation we have to have at some point. And I think we'd be open to them."

He called the Pfizer contract's revenue-share on higher foreign prices "a relatively creative idea... very, for lack of a better phrase, it's very like Trumpian."

Analyst/economist commentary:

  • On Vital Health Podcast, "VT Discusses MFN and Price Controls" (Oct 2), Vital Transformation CEO Duane Schulthess and economist Dr. Harry Bowen presented data on 44 top-selling drugs.
    • European prices went from roughly 40–45% below US prices in 2005 to 65–75% below by 2020.
    • Bowen's argument: with the US supplying "about 85% of all their profits," MFN pricing gives companies a reason to "withhold introducing drugs into new markets."
  • On the same Biotech Hangout episode, co-host Sam made the counter-argument. Europe "just can't afford to pay the extra cash." If prices do not even out, "the only option left is to raise prices in the U.S."

Why it matters. Mid-caps signing MFN deals would squeeze peak-sales assumptions for exactly the SMID names we track as targets. That lowers what an acquirer would pay. Watch whether ROIV, VRTX, ALNY or BIIB sign MFN deals.

The debate: supercycle or erosion?

The bull case: an M&A supercycle is coming. Pharma has more cash than ideas, and the clock is running.

The bear case: the cliff gets filled more cheaply than takeovers.

  • This week's evidence points to options, not control.
    • AZ bought 10% of Summit, not 100%.
    • Novo, Merck and Novartis paid about $1.3B upfront combined for three early-stage China-sourced assets.
    • Sanofi and Regeneron extended Dupixent internally and may have pushed its cliff from 2031 to 2037.
  • Reverse mergers are giving private biotechs another way to go public without a buyer. On BioCentury This Week, "Ep. 389" (Sept 29), BioCentury's Paul reported (journalist) that reverse mergers with concurrent nine-figure private placements are "almost as many as IPOs in 2026." Legacy shareholders of the shell company often get a CVR (contingent value right, a payout only if a future milestone is hit).
  • If the MFN pricing deals reach the mid-caps, what targets are worth to a buyer falls.

My take. Both sides are right about different parts of the market. The cliff is real and the money will be spent. Merck, Pfizer and BMY still face combined revenue gaps in the tens of billions by 2030, and wishful thinking doesn't fill that. But this week argued strongly that the money goes first into cheap, early, often China-sourced options and minority stakes. Full takeovers are kept for de-risked, late-stage or commercial assets where there is no cheaper way in.

For a book, that means:

  • own late-stage or launched SMID names with no China substitute (RVMD's RAS franchise, PCVX if OPUS-1 works);
  • be careful with early-stage names in crowded classes that were priced on takeout hopes;
  • treat SMMT as a binary data bet, not a takeout story.

AZ just showed that you do not have to buy the company to own the drug class.

Stocks in play

Ticker Bull case Bear case Next catalyst / number to watch
SMMT $2B AZ cash at a 19% premium removes funding risk; AZ and Daiichi co-fund trials; Citi $43 A strategic is paying for options, not control; HARMONi-3 may slip; Barclays $20 HARMONi-3 PFS (late 2026 or early 2027); PDUFA Nov 14
AZN Cheap entry into the PD-1/VEGF class (~10% of Summit); filed Orpathys + Tagrisso NDA (SAFFRON) Market reads the move as a hedge on its own lung trials (podcast speculation, no evidence) ESMO late Oct; MOU follow-on combinations
MRK Welireg combo approved; tulisokibart Phase 2b HS response 72%/64% vs 35%; PTs up to $180 I-DXd SCLC application withdrawn; $0.13 Q3 charge; no Keytruda Qlex US data AAO Oct 10 (remigromig); ESMO INTerpath-001; Q3 print
LLY EASD sweep: retatrutide TRIUMPH-2 up to 20.8% (23.4% at BMI ≥35); Foundayo ACHIEVE-4 all-cause death −57%; Jaypirca first-line CLL; JPM $1,500 Nektar jury verdict of $90M + interest; EloraTZP discontinuation for side effects up to 27%; zero room for error at ~$1.1T Retatrutide BLA Q1'27; bigger M&A in infectious disease, women's health or psychiatry
NVO Hengrui oral pill license; CagriSema 22.4% weight loss in fMRI study Licenses, not acquisitions; Viatris/Mylan paragraph IV challenge to a new semaglutide patent; shift to marketing slogans like "Summer Glow Up" First real acquisition; Delaware patent case
SNY Dupixent protection possibly to 2037 (one analyst's patent group view) Buy side thinks it overpaid; stock fell on the Regeneron deal Proof the IL-13 program can reach pivotal trials quickly
VRTX UBS $615; povetacicept (IgAN) could be the 8th approved therapy; CF cash pays for deals Crinetics close still not publicly confirmed; no MFN deal Crinetics close/guidance update; povetacicept PDUFA Nov 30
RVMD Rasonque launch; Merck's $400M for a pre-clinical G12D drug supports RAS franchise value; UBS $265 Insider selling (prior week); no bid Q3 launch numbers; ESMO
PFE Tilrekimig Phase 2 AD EASI-75 62.5% vs 19.9%; head-to-head Phase 3 vs Dupixent; Litfulo vitiligo Phase 3 positive Florida AG lawsuit vs Pfizer and Bourla; UBS Neutral $27 Q3 print; any BD after Metsera
PCVX OPUS-1 VAX-31 Phase 3 topline "this October" (Mizuho); BofA puts success odds at 75% Binary; BofA trimmed target to $130 OPUS-1 topline
INSM Brensocatib launch Barclays cut target to $207 from $237; Q3 script estimates "may be too optimistic" Q3 scripts; Arikayce PDUFA Jan 28, 2027
BMY Camzyos approved for children (FDA) No podcast strategy discussion; CAR-T autoimmune pause unresolved Admilparant IPF Phase 3 (likely October; UBS $80)
VKTX Funding in hand after the offering No takeout chatter this week; Amgen's monthly MariTide is a competitor VK2735 Phase 3 timelines

Read-throughs

  • SMID takeout targets. Minority stake plus co-funded trials is a new template, and it caps near-term control premiums for companies waiting on a binary readout. Expect other PD-1/VEGF and ADC developers to be offered similar deals rather than takeovers. Names with approved or launching products (RVMD, INSM) are less exposed to this, because a buyer cannot get the same thing more cheaply in China.
  • Biosimilar and generic makers. The Viatris/Mylan paragraph IV challenge in Delaware is a long-dated free option on semaglutide generics. On The Pen's host noted the fight decides "whether generic competition starts in 2030s" or later. If Dupixent really holds to 2037, that is bad news for future Dupixent biosimilars.
  • XBI / sentiment. XBI finished the week down 0.36% ($155.03 to $154.47), trading between $153.57 and $159.98. A $2B premium cheque into the most-watched SMID name did not lift the group. That fits the view that the market sees these deals as single-stock events, not proof of a takeout wave.
  • Bankers. Fee pools are shifting toward licensing, structured equity and reverse mergers with private placements (per BioCentury) rather than large public-company M&A advisory work.
  • CROs and pharma services. Contract research and services providers did see real M&A: House Calls, "Quick Hits: Pharma Services M&A" (Sept 30) discussed Thermo Fisher's $8.9B Clario acquisition. Co-funded combination trials like AZ–Summit–Daiichi mean more trial volume. A growing share of early trial work is moving to China, which is a long-term headwind for US-centric CROs.

What changed vs last week

Last week This week
Novo CEO "quite interested" in M&A; Nanexa license No acquisition. Another license instead (Hengrui, $300M upfront). Still saying it more than doing it.
Viking chose a ~$500M capital raise over a sale Offering reportedly closed upsized (web report, not independently verified). No takeover chatter on VKTX, GPCR or SMMT. SMMT got a strategic investor instead.
VRTX/CRNX close expected by 9/30 Still unconfirmed. We found no closing release. One web result claimed a Sept 1 close, but its link was dead, so we are not relying on it. The 8-K said 2026 guidance would be updated at closing (SEC).
Section 232 100% tariff live 9/29 It went live. No podcast discussion and no company reaction found. Web reports describe 0% rates for orphan drugs, cell and gene therapies, ADCs and companies with onshoring + MFN deals, which may explain the silence. Not independently verified.
GLOBE pricing model expected Oct 1 Correction: web reports say the final rule takes effect Nov 30 and the model starts Jan 1, 2027, with projected savings cut to about $440M. Not independently verified. No lawsuit filed.
Lilly/Nektar jury pending Verdict: Lilly breached the implied covenant of good faith; $90M plus interest, subject to post-trial proceedings (wire report).
EASD (retatrutide, eloralintide) upcoming Delivered. TRIUMPH-2 up to 20.8%; EloraTZP up to 23.3% but with high discontinuation (wire reports).
CAR-T pauses (zola-cel, rap-cel) No update.
MFN holdouts (VRTX, BIIB, ALNY) No new signings found; Roivant's CEO says MFN is "coming for the mid-caps."
Keytruda Qlex US conversion data missing Missing a seventh week.

Still quiet on podcasts (and that silence tells you something): Pfizer, AbbVie, J&J, Gilead and BMY had no strategic or M&A discussion. AbbVie only appeared through a small AI-discovery partnership with Iambic (Crain's Daily Gist, "An $85 million bet on in-house AI", Sept 28). These names were also missing:

  • SMID targets: MDGL, CYTK, INSM, KRYS, PCVX, SRRK and GPCR had no podcast chatter. ROIV appeared only in a Sjögren's discussion of its FcRn drug.
  • Themes: no podcast covered FTC/antitrust, and none discussed deal-specific CVRs.